Corbus Pharmaceuticals Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Corbus Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Corbus Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Corbus Pharmaceuticals saw a drop in short interest in February. As of February 26th, there was short interest totaling 13,580,000 shares, a drop of 38.7% from the February 11th total of 22,140,000 shares. Based on an average daily trading volume, of 14,750,000 shares, the short-interest ratio is currently 0.9 days.
View Corbus Pharmaceuticals' Short Interest.

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Corbus Pharmaceuticals.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Sunday, March, 14th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.15. The biopharmaceutical company earned $0.66 million during the quarter, compared to analysts' expectations of $1.24 million. Corbus Pharmaceuticals had a negative net margin of 2,208.06% and a negative trailing twelve-month return on equity of 485.45%.
View Corbus Pharmaceuticals' earnings history.

Corbus Pharmaceuticals' stock was trading at $4.12 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRBP stock has decreased by 56.2% and is now trading at $1.8050.
View which stocks have been most impacted by COVID-19.

8 equities research analysts have issued 12-month price targets for Corbus Pharmaceuticals' shares. Their forecasts range from $2.50 to $32.00. On average, they anticipate Corbus Pharmaceuticals' share price to reach $15.69 in the next twelve months. This suggests a possible upside of 769.1% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Corbus Pharmaceuticals include Vanda Pharmaceuticals (VNDA), Merus (MRUS), Vectura Group (VEGPF), BioXcel Therapeutics (BTAI), Dyne Therapeutics (DYN), Affimed (AFMD), Humanigen (HGEN), Epizyme (EPZM), ADVANZ PHARMA (CXRXF), Amphastar Pharmaceuticals (AMPH), Collegium Pharmaceutical (COLL), Karyopharm Therapeutics (KPTI), Lexicon Pharmaceuticals (LXRX), Intercept Pharmaceuticals (ICPT) and Esperion Therapeutics (ESPR).
View all of CRBP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CRBP stock can currently be purchased for approximately $1.81.

Corbus Pharmaceuticals has a market capitalization of $225.68 million and generates $36.14 million in revenue each year. The biopharmaceutical company earns $-71,450,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.

Corbus Pharmaceuticals employs 141 workers across the globe.

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

Corbus Pharmaceuticals is headquartered at 500 River Ridge Drive, Norwood MA, 02062.

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at 617-963-0100 or via email at [email protected]